Last reviewed · How we verify
Micardis plus 80/12.5
Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction.
Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction. Used for Hypertension (essential hypertension in patients requiring combination therapy).
At a glance
| Generic name | Micardis plus 80/12.5 |
|---|---|
| Sponsor | Heart Care Foundation |
| Drug class | Angiotensin II receptor blocker + thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Telmisartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, thereby reducing peripheral vascular resistance and blood pressure. Hydrochlorothiazide acts as a thiazide diuretic that increases sodium and water excretion, reducing blood volume and further lowering blood pressure. The combination provides synergistic antihypertensive effects.
Approved indications
- Hypertension (essential hypertension in patients requiring combination therapy)
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Headache
- Upper respiratory tract infection
Key clinical trials
- Arterial Stiffness and Blood Pressure (NA)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
- Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment (PHASE3)
- Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers (PHASE1)
- A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers (PHASE1)
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study (PHASE4)
- To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
- Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micardis plus 80/12.5 CI brief — competitive landscape report
- Micardis plus 80/12.5 updates RSS · CI watch RSS
- Heart Care Foundation portfolio CI